What Is Pleural Mesothelioma?
Pleural mesothelioma is a cancer of the pleura, the thin, two-layered membrane surrounding the lungs. It accounts for approximately 80% of all mesothelioma diagnoses, making it the most common form of this asbestos-related cancer.
The pleura consists of two layers:
- Parietal pleura: Lines the chest wall and diaphragm
- Visceral pleura: Covers the lungs
Between these layers is a small amount of fluid that allows the lungs to expand and contract smoothly during breathing. Pleural mesothelioma develops when inhaled asbestos fibers lodge in this lining and, over decades, cause malignant cellular changes.
Causes and Risk Factors
Asbestos Exposure
Asbestos is the only known cause of pleural mesothelioma. When asbestos-containing materials are disturbed, microscopic fibers become airborne and can penetrate deep into lung tissue, eventually reaching the pleural lining.
The body cannot break down or expel asbestos fibers. Over time, the fibers cause:
- Chronic inflammation
- Genetic mutations in mesothelial cells
- Oxidative stress and cellular damage
- Eventually, malignant transformation
High-Risk Groups
Symptoms of Pleural Mesothelioma
Symptoms typically don’t appear until the disease has progressed, which is why 65% of cases are diagnosed at Stage 3 or 4.
Early Symptoms
Advanced Symptoms
- Difficulty swallowing (dysphagia)
- Night sweats
- Unexplained weight loss
- Pleural effusion (fluid buildup around lungs)
- Lumps under the skin on the chest
- Facial or arm swelling
Why Symptoms Are Often Missed
Early pleural mesothelioma symptoms mimic common conditions like pneumonia, bronchitis, COPD, or even normal aging. Without known asbestos exposure history, physicians may not initially suspect mesothelioma.
If you have a history of asbestos exposure and experience respiratory symptoms, inform your healthcare provider about your exposure history. This context significantly changes how symptoms should be evaluated.
Diagnosis
Diagnostic Process
Diagnosing pleural mesothelioma typically involves multiple steps:
- Medical history and physical examination — Including detailed occupational history
- Imaging tests — Chest X-ray, CT scan, PET scan, MRI
- Tissue biopsy — Thoracoscopy, thoracotomy, or CT-guided needle biopsy
- Immunohistochemistry — Distinguishes mesothelioma from other cancers
Cell Types
| Cell Type | Frequency | Characteristics | Prognosis |
|---|---|---|---|
| Epithelioid | 50-70% | Most common; cells resemble normal tissue | Best |
| Sarcomatoid | 10-20% | Spindle-shaped cells; more aggressive | Poorest |
| Biphasic | 20-35% | Mix of both cell types | Intermediate |
Staging
Pleural mesothelioma uses the TNM staging system:
- T (Tumor): Size and extent of the primary tumor
- N (Nodes): Lymph node involvement
- M (Metastasis): Distant spread
| Stage | Description | Typical Treatment | Median Survival | 2-Year |
|---|---|---|---|---|
| Stage 1 | Localized — confined to pleural lining on one side | Surgery often possible (EPP or P/D) + chemotherapy | 19-22 months | 39% |
| Stage 2 | Regional — spread beyond pleura but on one side | Surgery may be possible + chemotherapy | 19 months | 39% |
| Stage 3 | Advanced regional — often involves lymph nodes | Chemo + immunotherapy; surgery for some | 18 months | 41% |
| Stage 4 | Distant metastasis — spread beyond the chest | Chemo, immunotherapy, palliative care | 13-15 months | 31% |
Only 9% of patients receive a Stage 1 diagnosis. This underscores the importance of reporting asbestos exposure history to healthcare providers.
Treatment Options
Surgery
Surgery is typically only an option for early-stage patients (approximately 20% of diagnoses) who are healthy enough to tolerate the procedure.
| Procedure | What It Removes | Best For | Recovery |
|---|---|---|---|
| Extrapleural Pneumonectomy (EPP) | Removes affected lung, pleural lining, part of diaphragm, and pericardium | Patients in good overall health | Longer |
| Pleurectomy/Decortication (P/D) | Removes pleural lining while preserving the lung | Most surgical candidates | Faster |
Chemotherapy
The standard first-line regimen combines Pemetrexed (Alimta) with cisplatin or carboplatin. This combination has been the standard of care for over 15 years.
Immunotherapy
Immunotherapy represents the first major advancement in mesothelioma treatment in 15 years. In October 2020, the FDA approved Opdivo (nivolumab) combined with Yervoy (ipilimumab) for first-line treatment.
Radiation Therapy
Radiation is typically used in combination with surgery and chemotherapy, or for palliative care to reduce tumor size, kill remaining cancer cells after surgery, and relieve pain and symptoms.
Multimodal Treatment
Patients who receive multimodal treatment — combining surgery, chemotherapy, and immunotherapy — achieve the best outcomes. Early-stage patients receiving this approach have achieved median survival of 32.1 months, nearly triple the overall median.
Survival Rates and Prognosis
Factors That Affect Prognosis
| Prognostic Factor | Effect on Prognosis |
|---|---|
| Earlier stage at diagnosis | Positive |
| Epithelioid cell type | Positive |
| Good overall health | Positive |
| Younger age | Positive |
| Female gender | Positive |
| Access to specialized treatment | Positive |
| Advanced stage (3-4) | Negative |
| Sarcomatoid or biphasic cell type | Negative |
| Poor performance status | Negative |
| Elevated blood LDH | Negative |
Living with Pleural Mesothelioma
Finding Specialized Care
Clinical Trials
Clinical trials provide access to emerging treatments before they’re widely available. Resources include:
- ClinicalTrials.gov
- NCI Cancer Information Service
- Mesothelioma treatment center trial programs
Support Resources
- Patient advocacy organizations
- Support groups for patients and caregivers
- Palliative care services
- Social workers specializing in cancer care
Prevention
For Current Workers
For Those with Past Exposure
What treatment options are available for my stage?▼
Stage 1-2 patients may be candidates for surgery (EPP or P/D) combined with chemotherapy and possibly radiation. Stage 3-4 typically involves chemotherapy and immunotherapy. Ask about clinical trials at any stage.
Am I a candidate for immunotherapy?▼
Nivolumab plus ipilimumab is now FDA-approved as first-line treatment. Your oncologist will consider your cell type, overall health, and treatment goals. Sarcomatoid tumors may particularly benefit from immunotherapy.
Should I get a second opinion?▼
Yes, particularly at a specialized mesothelioma center. These centers have more experience, access to clinical trials, and multidisciplinary teams that can identify treatment options you might not otherwise hear about.
What factors affect my prognosis?▼
Key factors include stage at diagnosis, cell type (epithelioid is best), overall health, age, gender (women have slightly better outcomes), and treatment received. Multimodal treatment at specialized centers produces the best outcomes.